These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

19 related articles for article (PubMed ID: 1532940)

  • 1. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
    Kässner F; Hodder R; Bateman ED
    Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease.
    Sestini P; Ram FS
    Cochrane Database Syst Rev; 2000; 2002(2):CD001495. PubMed ID: 10796652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.
    Thorax; 1997 Dec; 52 Suppl 5(Suppl 5):S1-28. PubMed ID: 9474238
    [No Abstract]   [Full Text] [Related]  

  • 4. Nebulisers for chronic obstructive pulmonary disease.
    O'Driscoll BR
    Thorax; 1997 Apr; 52 Suppl 2(Suppl 2):S49-52. PubMed ID: 9155851
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.
    Moayyedi P; Congleton J; Page RL; Pearson SB; Muers MF
    Thorax; 1995 Aug; 50(8):834-7. PubMed ID: 7570433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebuliser therapy.
    Teale C; Morrison JF; Jones PC; Muers MF
    Respir Med; 1991 Jul; 85(4):281-4. PubMed ID: 1835110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of domiciliary nebulizers in managing patients with severe COPD.
    Eiser N; Angus K; McHale S
    Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy.
    Goldman JM; Teale C; Muers MF
    Respir Med; 1992 Jan; 86(1):33-8. PubMed ID: 1533047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effects of anticholinergic and beta 2-agonist and combination therapy on respiratory impedance in COPD.
    Wesseling G; Mostert R; Wouters EF
    Chest; 1992 Jan; 101(1):166-73. PubMed ID: 1530836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of inhaled ipratropium bromide, fenoterol and their combination in COPD patients.
    Charoenpan P; Kiatboonsri S; Uswanopakhun P; Vongvivat K; Sulaimanee P
    J Med Assoc Thai; 1990 Feb; 73(2):91-5. PubMed ID: 2141057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation.
    Morrison JF; Jones PC; Muers MF
    Eur Respir J; 1992 Apr; 5(4):424-9. PubMed ID: 1532940
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.